halometasone and Acute-Disease

In a double-blind, randomized multicenter study in patients with acute episodes of atopic dermatitis, the efficacy and tolerance of 0.5% halometasone (Sicorten) cream were compared with those of 0.25% prednicarbate cream. A total of 165 patients (88 men, 77 women) were admitted to the study. The halometasone group contained 9% more cases with severe disease than did the prednicarbate group. Two daily nonocclusive applications were permitted, and treatment lasted 14 days. No difference in the onset of the effect was observed between the two groups. With respect to clinical efficacy, higher healing rates were found in the halometasone group: 50.6% versus 34.5% in the patients as a whole, and 39.5% vs. 16.2% in the subgroup of clinically severe cases. Applying stratification, a statistical difference was found in the clinically severe cases. Both creams were well tolerated; undesired side effects were observed neither with halometasone cream nor with prednicarbate cream. Cosmetic acceptance was assessed as very good by 50.6% of patients treated with halometasone cream, and 46.0% of patients treated with prednicarbate cream. Summarizing, it may be noted that halometasone cream is more effective than prednicarbate cream, and is equally well tolerated.

Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Child; Child, Preschool; Dermatitis, Atopic; Double-Blind Method; Female; Humans; Infant; Male; Middle Aged; Ointments; Prednisolone

A multicentre, between-patient, comparative trial was carried out to compare the efficacy and tolerability of a cream containing 0.05 halometasone and 1% triclosan with those of a cream with 0.05% betametasone dipropionate and 0.1% gentamicin sulphate in patients suffering from infected acute ezcematous dermatoses. In the evaluable trial population, consisting of 265 patients, halometasone/triclosan cream yielded a significantly (p = 0.001) higher success rate ('good' to 'very good' results), namely 96%, than the comparative cream (80%). Halometasone/triclosan cream also displayed a significantly (p = 0.008) higher cure rate (73.9%) than that observed with the comparative preparation (58.6%). The proportion of patients obtaining an early cure, i.e. in less than 20 days, was significantly (p = 0.0005) higher with halometasone/triclosan cream (42.5%) than with the comparative preparation (22.6%). The two preparations did not differ significantly with regard to the incidence and severity of adverse effects.

Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Clinical Trials as Topic; Drug Combinations; Eczema; Female; Gentamicins; Humans; Male; Middle Aged; Phenyl Ethers; Triclosan

In this multicentre, between-patient trial the efficacy and tolerability of a cream, containing 0.05% halometasone and 1% triclosan, was compared with those of Nerisona C cream, containing 0.1% diflucortolone valerate and 1% chlorquinaldol, in 183 patients with acute dermatomycoses. Halometasone/triclosan cream and the comparative cream showed closely similar results with respect to good to very good therapeutic effects (60% versus 57%). However, halometasone/triclosan cream proved superior to the comparative preparation with regard to very good (cured) results (53% versus 46%), an early cure in less than 30 days (41% versus 34%) and onset of action within 3 days of starting the treatment (32% versus 18%). Mycological findings were positive on direct microscopy in 36% and 43% and in culture in 19% and 17% of the patients following treatment with halometasone/triclosan cream and the comparative cream preparation, respectively. Adverse effects were reported in seven out of 108 patients treated with halometasone/triclosan cream and in five out of 107 patients treated with the comparative preparation.

Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Betamethasone; Chlorquinaldol; Clinical Trials as Topic; Dermatomycoses; Diflucortolone; Drug Combinations; Female; Fluocortolone; Humans; Hydroxyquinolines; Male; Middle Aged; Phenyl Ethers; Triclosan

Sixty children under 10 years of age (including 18 under 3 years) suffering from non-infected acute eczematous dermatoses were treated with 0.05% halometasone cream containing a new high-potency trihalogenated synthetic dermatocorticosteroid. The trial population consisted of patients with acute atopic dermatitis, seborrhoeic dermatitis, nummular dermatitis and contact dermatitis. Halometasone cream yielded very satisfactory results and showed excellent tolerability. It produced 'good' or 'very good' results in 90% of the cases and gave an overall cure rate of 74.3%. The number of patients obtaining an early cure, i.e. in less than 20 days, was thirty-seven (62%). The onset of action was reported in 78.3% of the patients within 3 days of starting the treatment. All patients tolerated the treatment well and no adverse effects, either due to the topical application or the transcutaneous systemic absorption of the corticoid, were reported.

Topics: Acute Disease; Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Child; Child, Preschool; Clinical Trials as Topic; Eczema; Female; Humans; Infant; Male